JP2018138596A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018138596A5 JP2018138596A5 JP2018090693A JP2018090693A JP2018138596A5 JP 2018138596 A5 JP2018138596 A5 JP 2018138596A5 JP 2018090693 A JP2018090693 A JP 2018090693A JP 2018090693 A JP2018090693 A JP 2018090693A JP 2018138596 A5 JP2018138596 A5 JP 2018138596A5
- Authority
- JP
- Japan
- Prior art keywords
- sirna
- administered
- use according
- eye
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004459 Small Interfering RNA Proteins 0.000 claims 14
- 239000002924 silencing RNA Substances 0.000 claims 14
- 206010013774 Dry eye Diseases 0.000 claims 3
- 206010015958 Eye pain Diseases 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Claims (11)
- ドライアイおよび/または眼痛を処置するための医薬の製造における配列番号1に示される塩基配列を標的化するsiRNAの使用であって、前記siRNAは、1日当たり約0.1〜約10mgの投与量で投与される、使用。
- 前記siRNAが、1日当たり約0.5〜約1.5mgの投与量で投与される、請求項1に記載の使用。
- 前記siRNAが、1日当たり約0.3〜約0.9mgの投与量で投与される、請求項1に記載の使用。
- 前記siRNAが、1日当たり眼1つ当たり約0.6mgまたは約0.9mgの投与量で投与される、請求項1に記載の使用。
- 前記siRNAが、5〜15日間投与される、請求項1から4のいずれか一項に記載の使用。
- 前記siRNAが、10日間投与される、請求項1から5のいずれか一項に記載の使用。
- 前記siRNAが、4週間超の期間投与される、請求項1から6のいずれか一項に記載の使用。
- 前記siRNAが、配列番号2として規定される化合物である、請求項1から7のいずれか一項に記載の使用。
- 前記siRNAが、眼に局所投与される、請求項1から8のいずれか一項に記載の使用。
- 1日当たり約0.1〜約10mgの投与量で投与される、ドライアイおよび/または眼痛の処置で使用するための、配列番号1に示される塩基配列を標的化するsiRNA。
- 配列番号1に示される塩基配列を標的化するsiRNAと、所定体積の液滴中に約0.3〜約0.9mgの投与量のsiRNAを分注するための開口部を伴う分注器と、前記配列番号1に示される塩基配列を標的化するsiRNAを、毎日投与するために約0.3〜約0.9mgの投与量で投与するための印刷された指示書とを供給することを含む、ドライアイおよび/または眼痛を処置するための医療用キット。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1215857.2 | 2012-09-05 | ||
GBGB1215857.2A GB201215857D0 (en) | 2012-09-05 | 2012-09-05 | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015530372A Division JP2015529210A (ja) | 2012-09-05 | 2013-09-04 | 眼の状態を処置および/または防止するためのsiRNAならびに方法および組成物におけるそれらの使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018138596A JP2018138596A (ja) | 2018-09-06 |
JP2018138596A5 true JP2018138596A5 (ja) | 2018-10-18 |
JP6742362B2 JP6742362B2 (ja) | 2020-08-19 |
Family
ID=47136985
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015530372A Pending JP2015529210A (ja) | 2012-09-05 | 2013-09-04 | 眼の状態を処置および/または防止するためのsiRNAならびに方法および組成物におけるそれらの使用 |
JP2018090693A Active JP6742362B2 (ja) | 2012-09-05 | 2018-05-09 | 眼の状態を処置および/または防止するためのsiRNAならびに方法および組成物におけるそれらの使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015530372A Pending JP2015529210A (ja) | 2012-09-05 | 2013-09-04 | 眼の状態を処置および/または防止するためのsiRNAならびに方法および組成物におけるそれらの使用 |
Country Status (30)
Country | Link |
---|---|
US (1) | US9808479B2 (ja) |
EP (1) | EP2893019B1 (ja) |
JP (2) | JP2015529210A (ja) |
KR (1) | KR102136539B1 (ja) |
CN (2) | CN104640988A (ja) |
AU (1) | AU2013311781B2 (ja) |
BR (1) | BR112015004469B8 (ja) |
CA (1) | CA2883040C (ja) |
CL (1) | CL2015000537A1 (ja) |
CY (1) | CY1121000T1 (ja) |
DK (1) | DK2893019T3 (ja) |
EC (1) | ECSP15009391A (ja) |
ES (1) | ES2685346T3 (ja) |
GB (1) | GB201215857D0 (ja) |
HK (1) | HK1212377A1 (ja) |
HR (1) | HRP20181079T1 (ja) |
HU (1) | HUE040096T2 (ja) |
IL (1) | IL237389B (ja) |
IN (1) | IN2015DN02501A (ja) |
LT (1) | LT2893019T (ja) |
MX (1) | MX362854B (ja) |
PE (1) | PE20150619A1 (ja) |
PL (1) | PL2893019T3 (ja) |
PT (1) | PT2893019T (ja) |
RS (1) | RS57620B1 (ja) |
RU (1) | RU2663100C2 (ja) |
SG (1) | SG11201501386TA (ja) |
SI (1) | SI2893019T1 (ja) |
WO (1) | WO2014037377A1 (ja) |
ZA (1) | ZA201501494B (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6165723B2 (ja) | 2011-06-30 | 2017-07-19 | アローヘッド ファーマシューティカルズ インコーポレイテッド | B型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法 |
KR20180038465A (ko) | 2015-08-07 | 2018-04-16 | 애로우헤드 파마슈티컬스 인코포레이티드 | B형 간염 바이러스 감염에 대한 rnai 치료법 |
JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
JP6994061B2 (ja) | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤 |
CN113453686A (zh) | 2019-02-15 | 2021-09-28 | 诺华股份有限公司 | 治疗眼表痛的方法 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4343794A (en) | 1980-05-06 | 1982-08-10 | Mt. Sinai | Method of reducing intraocular pressure with salts of vanadic acid |
US4652586A (en) | 1980-11-07 | 1987-03-24 | The General Hospital Corporation | Selective beta-2 adrenergic antagonists for the treatment of glaucoma |
US4617299A (en) | 1983-12-19 | 1986-10-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
US5242943A (en) | 1984-03-28 | 1993-09-07 | William J. Louis | 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them |
US4812448A (en) | 1984-10-22 | 1989-03-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
US4757089A (en) | 1985-06-14 | 1988-07-12 | Massachusetts Eye And Ear Infirmary | Increasing aqueous humor outflow |
US5075323A (en) | 1988-08-24 | 1991-12-24 | Aktiebolaget Hassle | Compounds including omeprazole in the treatment of glaucoma |
US5260059A (en) | 1989-04-14 | 1993-11-09 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University | Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor |
US6372249B1 (en) | 1991-12-16 | 2002-04-16 | Baylor College Of Medicine | Senscent cell-derived inhibitors of DNA synthesis |
US5464866A (en) | 1992-08-17 | 1995-11-07 | Alcon Laboratories, Inc. | Substituted hydrindanes for the treatment of angiogenesis-dependent diseases |
US5545626A (en) | 1994-01-19 | 1996-08-13 | The Trustees Of Columbia University In The City Of New York | Method of treating glaucoma with oligonucleotides |
US5585401A (en) | 1994-12-09 | 1996-12-17 | The Reents Of The University Of California | Method for enhancing outflow of aqueous humor in treatment of glaucoma |
US20020055536A1 (en) | 1996-09-26 | 2002-05-09 | Dewitte Robert S. | System and method for structure-based drug design that includes accurate prediction of binding free energy |
US6489307B1 (en) | 1998-09-14 | 2002-12-03 | University Of Florida | Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use |
EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
US6365576B1 (en) | 1999-06-24 | 2002-04-02 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method for inhibiting herpes infection |
ES2215494T5 (es) | 2000-12-01 | 2017-12-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Moléculas de RNA pequeñas que median la interferencia de RNA |
US20020165158A1 (en) | 2001-03-27 | 2002-11-07 | King George L. | Methods of modulating angiogenesis |
US20070049543A1 (en) | 2001-05-18 | 2007-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA |
US20040209832A1 (en) | 2001-11-30 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
AU2002361861A1 (en) | 2001-12-21 | 2003-07-30 | Rhode Island Hospital | SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF |
US7294504B1 (en) | 2001-12-27 | 2007-11-13 | Allele Biotechnology & Pharmaceuticals, Inc. | Methods and compositions for DNA mediated gene silencing |
GB2406568B (en) | 2002-02-20 | 2005-09-28 | Sirna Therapeutics Inc | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
JP5578388B2 (ja) | 2002-04-18 | 2014-08-27 | オプコ ファーマシューティカルズ、エルエルシー | 中枢神経システム及び/若しくは眼の細胞及び組織中の遺伝子の特異的阻害のための手段と方法 |
US20040115641A1 (en) | 2002-12-11 | 2004-06-17 | Isis Pharmaceuticals Inc. | Modulation of ROCK 1 expression |
US20040146858A1 (en) | 2002-07-24 | 2004-07-29 | Immusol, Inc. | Novel siRNA gene libraries and methods for their production and use |
US20040115815A1 (en) | 2002-07-24 | 2004-06-17 | Immusol, Inc. | Single promoter system for making siRNA expression cassettes and expression libraries using a polymerase primer hairpin linker |
PT1527176E (pt) | 2002-08-05 | 2007-04-30 | Atugen Ag | Novas formas de muléculas de arn de interferência |
US20040029275A1 (en) | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
WO2004029212A2 (en) | 2002-09-25 | 2004-04-08 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
WO2004042024A2 (en) | 2002-11-01 | 2004-05-21 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF HIF-1 ALPHA |
DE10322662A1 (de) | 2002-11-06 | 2004-10-07 | Grünenthal GmbH | Wirksame und stabile DNA-Enzyme |
US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
EP1560931B1 (en) | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
US20060257851A1 (en) | 2002-11-26 | 2006-11-16 | Itzhak Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
US20040167090A1 (en) | 2003-02-21 | 2004-08-26 | Monahan Sean D. | Covalent modification of RNA for in vitro and in vivo delivery |
GB0307206D0 (en) | 2003-03-28 | 2003-04-30 | Axordia Ltd | Hyperproliferation |
US20040198640A1 (en) | 2003-04-02 | 2004-10-07 | Dharmacon, Inc. | Stabilized polynucleotides for use in RNA interference |
WO2004099372A2 (en) | 2003-05-01 | 2004-11-18 | University Of Florida | Anti-scarring ribozymes and methods |
US20040224405A1 (en) | 2003-05-06 | 2004-11-11 | Dharmacon Inc. | siRNA induced systemic gene silencing in mammalian systems |
EP1636342A4 (en) | 2003-06-20 | 2008-10-08 | Isis Pharmaceuticals Inc | OLIGOMERIC COMPOUNDS FOR GENE MODULATION |
WO2005034870A2 (en) | 2003-10-07 | 2005-04-21 | Renovis, Inc. | Amide compounds and ion channel ligands and uses thereof |
WO2005045037A2 (en) | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
KR20050039573A (ko) | 2003-10-23 | 2005-04-29 | 주식회사 태평양 | 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물 |
US20050208658A1 (en) | 2003-11-21 | 2005-09-22 | The University Of Maryland | RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression |
KR20150006902A (ko) * | 2003-12-03 | 2015-01-19 | 코다 테라퓨틱스 (엔지) 리미티드 | 코넥신에 표적화된 안티센스 화합물 및 그의 사용 방법 |
US7544803B2 (en) | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
WO2005076998A2 (en) | 2004-02-05 | 2005-08-25 | Intradigm Corporation | Rnai therapeutics for treatment of eye neovascularization diseases |
GB0403600D0 (en) | 2004-02-18 | 2004-03-24 | Trinity College Dublin | Methods and reagents for treating disease |
ES2423060T3 (es) | 2004-03-12 | 2013-09-17 | Alnylam Pharmaceuticals, Inc. | Agentes iRNA que tienen como diana al VEGF |
KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
WO2005117938A2 (en) | 2004-04-13 | 2005-12-15 | Regents Of The University Of Minnesota | Methods of treating ocular conditions |
US7687665B2 (en) | 2004-06-24 | 2010-03-30 | Incyte Corporation | 2-methylprop anamides and their use as pharmaceuticals |
WO2006020768A2 (en) | 2004-08-10 | 2006-02-23 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides |
US8030284B2 (en) | 2004-08-23 | 2011-10-04 | Sylentis S.A.U. | Treatment of eye disorders characterized by an elevated intraocular pressure by siRNAs |
TW200639252A (en) | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular hypertension targets |
CA2598234A1 (en) | 2005-03-11 | 2006-09-21 | Alcon, Inc. | Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma |
GB0521351D0 (en) | 2005-10-20 | 2005-11-30 | Genomica Sau | Modulation of TRPV expression levels |
CN101517081A (zh) * | 2006-08-24 | 2009-08-26 | 爱尔康研究有限公司 | RNAi介导的Gremlin抑制用于治疗眼内压相关的状况 |
US20110160279A1 (en) | 2007-08-13 | 2011-06-30 | Board Of Trustees Of Southern Illinois University | METHODS FOR TREATMENT AND PREVENTION OF OTOTOXICITY BY siRNA |
TW200927192A (en) * | 2007-11-19 | 2009-07-01 | Alcon Res Ltd | Use of TRPV1 receptor antagonists for treating dry eye and ocular pain |
CN201337650Y (zh) * | 2009-01-06 | 2009-11-04 | 河北科技大学 | 一次性药用单剂量液体容器 |
EP2390327A1 (en) * | 2010-05-27 | 2011-11-30 | Sylentis S.A. | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
-
2012
- 2012-09-05 GB GBGB1215857.2A patent/GB201215857D0/en not_active Ceased
-
2013
- 2013-09-04 ES ES13759707.6T patent/ES2685346T3/es active Active
- 2013-09-04 HU HUE13759707A patent/HUE040096T2/hu unknown
- 2013-09-04 IN IN2501DEN2015 patent/IN2015DN02501A/en unknown
- 2013-09-04 MX MX2015002802A patent/MX362854B/es active IP Right Grant
- 2013-09-04 PE PE2015000282A patent/PE20150619A1/es not_active Application Discontinuation
- 2013-09-04 LT LTEP13759707.6T patent/LT2893019T/lt unknown
- 2013-09-04 SI SI201331090T patent/SI2893019T1/sl unknown
- 2013-09-04 US US14/425,459 patent/US9808479B2/en active Active
- 2013-09-04 SG SG11201501386TA patent/SG11201501386TA/en unknown
- 2013-09-04 JP JP2015530372A patent/JP2015529210A/ja active Pending
- 2013-09-04 BR BR112015004469A patent/BR112015004469B8/pt active IP Right Grant
- 2013-09-04 EP EP13759707.6A patent/EP2893019B1/en active Active
- 2013-09-04 AU AU2013311781A patent/AU2013311781B2/en active Active
- 2013-09-04 CA CA2883040A patent/CA2883040C/en active Active
- 2013-09-04 WO PCT/EP2013/068245 patent/WO2014037377A1/en active Application Filing
- 2013-09-04 PL PL13759707T patent/PL2893019T3/pl unknown
- 2013-09-04 DK DK13759707.6T patent/DK2893019T3/en active
- 2013-09-04 CN CN201380046215.0A patent/CN104640988A/zh active Pending
- 2013-09-04 RS RS20180877A patent/RS57620B1/sr unknown
- 2013-09-04 PT PT13759707T patent/PT2893019T/pt unknown
- 2013-09-04 KR KR1020157006165A patent/KR102136539B1/ko active IP Right Grant
- 2013-09-04 CN CN201810353730.8A patent/CN108354944A/zh active Pending
- 2013-09-04 RU RU2015112121A patent/RU2663100C2/ru active
-
2015
- 2015-02-24 IL IL237389A patent/IL237389B/en active IP Right Grant
- 2015-03-04 CL CL2015000537A patent/CL2015000537A1/es unknown
- 2015-03-04 ZA ZA2015/01494A patent/ZA201501494B/en unknown
- 2015-03-12 EC ECIEPI20159391A patent/ECSP15009391A/es unknown
-
2016
- 2016-01-05 HK HK16100039.5A patent/HK1212377A1/xx unknown
-
2018
- 2018-05-09 JP JP2018090693A patent/JP6742362B2/ja active Active
- 2018-07-11 HR HRP20181079TT patent/HRP20181079T1/hr unknown
- 2018-08-10 CY CY181100845T patent/CY1121000T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018138596A5 (ja) | ||
EP4272818A3 (en) | Thrombolytic agent for the treatment of thromboembolism | |
JP2016106150A5 (ja) | ||
AR099078A2 (es) | Un medicamento que comprende acetato de glatiramer | |
NZ714963A (en) | Compositions and methods for treating anemia | |
EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
JP2013155188A5 (ja) | ||
NZ707377A (en) | Combination therapy methods for treating proliferative diseases | |
RU2010141579A (ru) | Режим дозировки селективного агониста рецептора s1p1 | |
CA2570474A1 (en) | A combination composition comprising paracetamol and ibuprofen | |
PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
JP2018513188A5 (ja) | ||
WO2009104932A3 (ko) | 복합제제 | |
BRPI0510895A (pt) | formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t | |
RU2015109296A (ru) | Системы доставки лекарственного средства и способы лечения рака мочевого пузыря, включающие применение оксалиплатина | |
RU2013123646A (ru) | Комбинированная композиция | |
RU2015109298A (ru) | Системы доставки лекарственного средства и способы лечения заболевания предстательной железы, включающие применение гемцитабина | |
HRP20181079T1 (hr) | Sirnk i njena primjena u metodama i kompozicijama za liječenje i/ili prevenciju očnih stanja | |
JP2016505050A5 (ja) | ||
MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
IL194500A0 (en) | Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application | |
JP2019529569A5 (ja) | ||
JP2019535830A5 (ja) | ||
AR111803A1 (es) | Derivado de ciclopentan[g]quinazolin-4-ona y su empleo en el tratamiento de cáncer resistente al platino |